Intercept Pharmaceuticals Inc (NASDAQ:ICPT) reported Q2 2018 earnings this Morning, coming in at ($2.58) per share, beating Wall Street’s estimates of ($2.88) per Share. Revenue for the quarter came in at $43.58 million beating analyst estimates of $41.26 million Recent Insider Trading for Intercept Pharmaceuticals Inc (NASDAQ:ICPT)
- On 4/9/2018 Francesco Micheli, Major Shareholder, bought 390,625 with an average share price of $64.00 per share and the total transaction amounting to $25,000,000.00.
- On 4/9/2018 Keith Michael Gottesdiener, Director, bought 1,171 with an average share price of $64.00 per share and the total transaction amounting to $74,944.00.
- On 4/9/2018 Mark Pruzanski, CEO, bought 7,812 with an average share price of $64.00 per share and the total transaction amounting to $499,968.00.
- On 10/2/2017 David Shapiro, CMO, sold 349 with an average share price of $58.90 per share and the total transaction amounting to $20,556.10.
- On 10/2/2017 Mark Pruzanski, CEO, sold 1,532 with an average share price of $58.87 per share and the total transaction amounting to $90,188.84.
- On 10/2/2017 Rachel Mcminn, Insider, sold 283 with an average share price of $58.89 per share and the total transaction amounting to $16,665.87.
About Company Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.Recent Analyst Rating for Intercept Pharmaceuticals Inc (NASDAQ:ICPT)
Recent Trading for Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Shares of Intercept Pharmaceuticals Inc closed the previous trading session at 100.83 up +9.05 9.86% with 1213400 shares trading hands.